Nektar Therapeutics (NKTR)

1.3200 -0.0300 (-2.22%) 收市：04:00PM EDT

Nektar Therapeutics

455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
415 482 5300
https://www.nektar.com

版塊: Healthcare
行業: Biotechnology
全職員工: 137

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Howard W. Robin	CEO, President & Director	1.83M	無	1953
Mr. Mark A. Wilson	Senior VP, Chief Legal Officer & Secretary	749.99k	無	1972
Dr. Jonathan Zalevsky Ph.D.	Chief Research & Development Officer	1.25M	無	1975
Ms. Sandra A. Gardiner	Interim Chief Financial Officer	無	無	1966
Vivian Wu	Director of Investor Relations & Corporate Affairs	無	無	無
Mr. Robert Bacci	Senior Vice President of Human Resources & Facilities Operations	無	無	無
Ms. Jennifer Ruddock	Chief Business Officer	無	無	無
Dr. Mary Tagliaferri L.Ac., M.D.	Chief Medical Officer	無	無	1966

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

公司管治

截至 2024年4月1日 止，Nektar Therapeutics 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：8；董事會：7；股東權利：2；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。